Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024
Research and Development Intra-Cellular Therapies, Neurology, clinical trial, major depressive disorder, mental health

Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants …

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024
Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …

GSK’s meningococcal vaccine candidate accepted for FDA review

April 16, 2024
Medical Communications FDA, GSK, Immunology, meningococcal

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) …

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

April 15, 2024
Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …

FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

April 15, 2024
Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …

Lipocine announces results from phase 2 trial for obesity drug

April 12, 2024
Research and Development Lipocine, Obesity, clinical trial, weight loss

Lipocine Inc has announced results from its phase 2 clinical trial (NCT04134091), which includes results for LPCN 2401, the company’s …

Baxter expands US portfolio with new injectables

April 12, 2024
Medical Communications Pharmacy, baxter, injectables, product launch

Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of five new injectable products in …

Vertex to acquire Alpine Immune Sciences for $4.9bn

April 11, 2024
Business Services Alpine Immune Sciences, Nephrology, Vertex pharmaceuticals, acquisition, nephropathy

Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will …

NICE recommends migraine treatment for NHS use

April 11, 2024
Medical Communications NHS, NICE, Neurology, migraine

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

April 10, 2024
Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …

FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment

April 10, 2024
Research and Development FDA, Oncology, Oryzon, lung cancer

Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …

An overview of women’s health in 2024

April 9, 2024
Reproductive health, abortion, fertility, reproductive health, women's health

Betsy Goodfellow from Pharmafocus considers the current landscape of women’s health, covering recent debates and ongoing issues within the reproductive health sphere …

Gilead’s Veklury recommended by NICE for COVID-19 treatment

April 9, 2024
Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …

PureTech Health launches Seaport Therapeutics

April 9, 2024
Business Services Financing, Neurology, PureTech Health, launch

PureTech Health has announced key progress on its ‘strategic initiatives to deliver innovative medicines to patients and unlock value for …

Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine

April 8, 2024
Research and Development Cancer, Geneos Therapeutics, Oncology, clinical trial

Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from the full cohort of patients …

Johnson & Johnson to acquire Shockwave Medical

April 8, 2024
Business Services Cardiology, Johnson & Johnson, Shockwave Medical, acquisition

Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J …

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

April 5, 2024
Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …

FDA accepts UCB’s sBLA for Bimzelx

April 5, 2024
Medical Communications Bimzelx, FDA, Pharmacy, UCB, sBLA

UCB has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application …

FDA approves Basilea’s antibiotic Zevtera for three indications

April 4, 2024
Medical Communications Basilea Pharmaceutica, FDA, Infections and infestations, Zevtera, antibiotic

Basilea Pharmaceutica has announced that the US Food and Drug Administration (FDA) has approved Zevtera (ceftobiprole medocaril sodium for injection), …

Ironic Biotech announces $1m funding to develop iron deficiency and anaemia treatment

April 4, 2024
Sales and Marketing Haematology, Ironic Biotech, anaemia, funding, iron deficiency

Swedish biotech startup Ironic Biotech has announced that it has successfully closed a pre-seed funding round of $1m, led by …

Latest content